CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ — Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas,…

Read the full release →

News provided by PR Newswire.